Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX)

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. amendment to a Schedule 13G shows Morgan Stanley reporting shared voting power of 2,930,734 shares and shared dispositive power of 2,959,296 shares in the issuer's common stock. The filing states the position equals 2.6% of the class.

The filing includes the statement, verbatim, that "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." The form lists CUSIP 46489V302 and is signed by an authorized Morgan Stanley signatory on 05/12/2026.

Insights

Compliance Counsel

Schedule 13G/A updates holdings and ownership status for an institutional filer.

The amendment records shared voting and shared dispositive power figures and cites Release No. 34-39538 for unit aggregation. It also includes the issuer CUSIP and an attestation that Morgan Stanley fell below the five percent beneficial-ownership threshold.

Timing: the signature date is 05/12/2026. The filing preserves standard qualifiers about aggregated MS Reporting Units; subsequent filings will show any material shifts.

Key Figures

Percent of class: 2.6% Shared voting power: 2,930,734 shares Shared dispositive power: 2,959,296 shares +2 more

5 metrics

Percent of class 2.6% reported percentage ownership

Shared voting power 2,930,734 shares shared voting power as reported on Schedule 13G/A

Shared dispositive power 2,959,296 shares shared dispositive power as reported on Schedule 13G/A

Amount beneficially owned 2,959,296 shares beneficial ownership figure shown on cover page

CUSIP 46489V302 identifier for Perspective Therapeutics common stock

Key Terms

Schedule 13G/A, beneficial owner, shared dispositive power, Release No. 34-39538, +1 more

5 terms

Schedule 13G/A regulatory

"Item 1. (a) Name of issuer: Perspective Therapeutics, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial owner regulatory

"As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared dispositive power financial

"Shared Dispositive Power 2,959,296.00"

Release No. 34-39538 regulatory

"In Accordance with the Release No. 34-39538 (January 12, 1998)"

MS Reporting Units other

"the "MS Reporting Units" of Morgan Stanley and its subsidiaries"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Perspective Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

46489V302

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 46489V302

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,930,734.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,959,296.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,959,296.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.6 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Perspective Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA, 98121
Item 2.
(a)	Name of person filing: Morgan Stanley
(b)	Address or principal business office or, if none, residence: 1585 Broadway, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 46489V302
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 2.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	05/12/2026

FAQ

What does Morgan Stanley report owning in CATX common stock?

Morgan Stanley reports shared voting power of 2,930,734 shares and shared dispositive power of 2,959,296 shares. The filing states this position represents 2.6% of the class and appears on a Schedule 13G/A amendment.

Has Morgan Stanley exceeded 5% ownership in CATX?

No. The amendment states "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." The signature date on the form is 05/12/2026.

What legal aggregation does the filing reference for CATX holdings?

The filing follows Release No. 34-39538, aggregating holdings across MS Reporting Units. That means certain Morgan Stanley operating units' positions are combined under the Release's rules for this Schedule 13G/A.

Who signed the Schedule 13G/A for Morgan Stanley?

Claire Gordon, an authorized signatory for Morgan Stanley, signed the amendment. The signature block on the form shows the filing attestation dated 05/12/2026.

What CUSIP and class are reported in this CATX filing?

The form identifies the security as Common Stock with CUSIP 46489V302. The filing names the issuer as Perspective Therapeutics, Inc. and gives the issuer's principal office address.